The US FDA has suspended the biologics license for Valneva’s live-attenuated chikungunya virus vaccine, Ixchiq, citing serious adverse events consistent with chikungunya-like illness and at least one death directly attributable to the vaccine. This suspension mandates immediate cessation of U.S. sales and shipments. The decision follows reports raising safety concerns, underscoring regulatory vigilance for emerging vaccine safety data.